

# Immunohematology Case Studies 2017 - 3

### A Tale of Two T-Cells



Dhana Gounder and Alison Badger New Zealand Blood Service Auckland, New Zealand dhana.gounder@nzblood.co.nz

### Clinical History



#### **Presenting History:**

- Nine year old Asian male admitted in November 2013 with two week history of intermittent fevers, abdominal distension, epigastric pain, occasional cough and weight loss
- Clinical examination revealed tender hepatosplenomegaly and widespread lymphadenopathy
- Blood tests: anaemia(Hb 98g/L); thrombocytopaenia (platelets 31 x 10<sup>9</sup>/L); raised liver enzymes
- Bone Marrow diagnosis Haemophagocytic lymphohistiocytosis (HLH)

### Clinical History



#### **Management and Progress**

- Initial response to HLH therapy but weaning associated with return of cytopaenia and organomegaly
- 26/07/14 received matched unrelated donor bone marrow transplantation
- June, 2015 developed late post-transplant immune haemolytic anaemia requiring steroid therapy and a 4 week course of Rituximab. Transfusion dependent.
- June, 2015 developed red cell alloantibodies

### Serologic History



- Negative antibody screen from initial presentation in November 2013 to August 2014
- Transfused 4 red cells between 08/11/13 and 13/08/14
- June 2015 auto AHG reactive antibody with anti-E and anti-c, DAT positive (IgG + C3d)
- Unable to exclude anti-Jk<sup>a</sup> with adsorbed plasma
- Transfusion commenced with O R<sub>1</sub>R<sub>1</sub> K- Jk(a-) red cells
- Genotyping performed 22/06/15 on whole blood sample – patient predicted to be R<sub>1</sub>R<sub>2</sub>, K- k+, Jk(a+b+), Fy(a+b-), M+N+S+s+
- Are the anti-E and anti-c autoantibodies?

### Sample Presentation Data



ABO/Rh: AB Pos (mixed field evident)

DAT: Positive (IgG + C3d)

Antibody Screen Method: Gel IAT

Antibody Screen Results: Positive

Antibody Identification Method: Gel IAT

Antibody Identification Preliminary Results: auto

AHG and Enzyme reactive antibody

Original blood group of patient O Positive, donor Bone Marrow AB Positive

## Sample Presentation Data using Native Plasma.



D	C	С	Е	е	Cw	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	М	N	S	S	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	Gel IAT	Gel ENZ
+	0	+	0	+	0	+	+	0	+	+	0	+	0	+	0	+	0	+	3+	4+
+	+	0	0	+	+	0	+	+	0	0	+	+	0	+	0	+	+	0	3+	4+
+	+	0	0	+	0	0	+	+	0	0	0	0	+	0	+	0	0	0	1+	4+
+	+	0	0	+	+	+	+	0	+	+	+	+	+	0	+	0	0	+	1+	4+
+	+	+	+	0	0	0	+	0	+	+	+	+	0	0	+	+	+	0	4+	4+
+	0	+	+	0	0	+	+	+	+	0	+	+	0	+	0	0	0	+	4+	4+
0	+	+	0	+	0	+	+	+	+	+	+	0	+	0	+	0	0	+	2+	4+
0	0	+	0	+	0	0	+	0	+	+	0	+	0	+	0	+	0	+	4+	4+
0	0	+	0	+	0	0	+	0	+	+	0	+	+	+	+	+	+	0	3+	4+
0	0	+	0	+	0	0	+	+	0	0	+	0	+	0	+	+	0	0	3+	4+
0	0	+	0	+	0	+	0	+	0	+	+	+	0	0	+	+	0	+	3+	4+
+	+	0	+	+	0	0	+	+	+	+	0	+	+	0	+	+	0	+	4+	4+
																	Αι	uto	4+	4+

## Further Work Allo Adsorption



D	С	С	E	е	Cw	K	k	Fy <sup>a</sup>	Fy <sup>b</sup>	Jk <sup>a</sup>	Jk <sup>b</sup>	М	N	S	s	P <sub>1</sub>	Le <sup>a</sup>	Le <sup>b</sup>	ABS R1R1	ABS R2R2	ABS rr
+	0	+	0	+	0	+	+	0	+	+	0	+	0	+	0	+	0	+	wk	0	0
+	+	0	0	+	+	0	+	+	0	0	+	+	0	+	0	+	+	0	0	0	0
+	+	0	0	+	0	0	+	+	0	0	0	0	+	0	+	0	0	0	0	0	0
+	+	0	0	+	+	+	+	0	+	+	+	+	+	0	+	0	0	+	0	0	0
+	+	+	+	0	0	0	+	0	+	+	+	+	0	0	+	+	+	0	3+	0.5	3+
+	0	+	+	0	0	+	+	+	+	0	+	+	0	+	0	0	0	+	3+	0.5	3+
0	+	+	0	+	0	+	+	+	+	+	+	0	+	0	+	0	0	+	wk	0	0
0	0	+	+	+	0	0	+	0	+	+	0	+	0	+	0	+	0	+	3+	1+	3+
0	0	+	0	+	0	0	+	0	+	+	0	+	+	+	+	+	+	0	0.5	0	0
0	0	+	0	+	0	0	+	+	0	0	+	0	+	0	+	+	0	0	0.5	0	0
0	0	+	0	+	0	+	0	+	0	+	+	+	0	0	+	+	0	+	wk	0	0
+	+	0	+	+	0	0	+	+	+	+	0	+	+	0	+	+	0	+	2+	0	2+

Four samples received between 13/06/15 and 24/06/15 all with the same serological picture of auto AHG reactive antibody with anti-E plus anti-c underlying.

### Challenge with the Current Presentation



- Continued transfusion over 1 week period
- T cell chimerism showed 70% donor 30% patient cell populations
- Genotyping will detect DNA from both populations
- Post transplant genotype: R<sub>1</sub>R<sub>2</sub>, K- k+, Jk(a+b+), Fy(a+b-), M+N+S+s+
- Patient and donor pre transplant samples obtained and genotyped again
- Patient genotype: R<sub>1</sub>R<sub>2</sub>, K- k+, Jk(a+b+), Fy(a+b-), M+N+S-s+
- Donor genotype: R<sub>1</sub>R<sub>1</sub>, K- k+, Jk(a-b+), Fy(a+b-), M+N-S+s+

## Patient Genotyping Post Transplant using inno-train RBC-Ready Gene





International Society of Blood Transfusion


### **BMT Donor Genotype**





### Patient Pre Transplant Genotype





### Challenge with the Current Presentation



 Younger patients are slow to engraft as they are very immune competent.

- Has the immuno competent graft formed allo antibodies against the recipient (GvHD)?
   Or..
- Are the antibodies auto antibodies formed by the patient?

## Interim Antibody Identification Possible Answers and Next Steps



- Patient genotype: R<sub>1</sub>R<sub>2</sub>, K- k+, Jk(a+b+), Fy(a+b-), M+N+S-s+
- Donor genotype: R<sub>1</sub>R<sub>1</sub>, K- k+, Jk(a-b+), Fy(a+b-), M+N-S+s+
- Red cells selected for transfusion :
  - R<sub>1</sub>R<sub>1</sub>, K-, Jk(a-), Fy(b-), S-
- Because it is unknown whether the antibodies are directed against the patient or donor cells, the 2 genotypes were compared and antigen negative red cells selected for any potential antibody that could be stimulated.

### **Updated Clinical Information**



- Patient transfusion dependence decreasing in frequency
- Last transfusion 2<sup>nd</sup> November 2015
- Currently managed on low dose sirolimus with excellent effect
- Mixed chimerism which is stable

#### Conclusions



- It is still unknown whether the antibodies are directed against the recipient or the donor cells
- Is this the donor lymphocytes giving rise to formation of alloantibodies or is this an autoimmune phenomenon?
  - Patient will be maintained on a transfusion protocol requiring R₁R₁, K-, Jk(a-), Fy(b-), S- RBC units

### Lessons Learned by the Case



- A full clinical history is always helpful!
- Be aware of transplant status before considering genotyping
- Chimerism can be a limitation with techniques such as genotyping where DNA is amplified
- Testing is unable to discriminate between the 2 different DNA populations
- Consider all possibilities when it comes to antibody production

#### References



- Khalil, A et al. Autoimmune Complications after Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Disorders. The Scientific World Journal 2014;3.
- 2. Seo, Jong Jin. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies. Blood Research 2015;50.
- 3. Shenoy, Shalini. Professor of Pediatrics, Stem Cell Transplants for Sickle Cell Disease Consequences of Chimerism.